The order carried out as a part of the projects titled:
STRATEGMED: DEVELOPMENT OF NEW CANCER THERAPIES BASED ON SELECTIVE ANTITUMOR IMMUNOMODULATORS (STRATEGMED2/265503/3/NCBR/15)
ARG: „PRE-CLINICAL AND CLINICAL DEVELOPMENT OF ARGINASE INHBITOR FOR CANCER IMMUNOTHERAPY” (POIR.01.01.01-00-415/17)
co-financed by the National and European Union Funds and because of the competitiveness principle.
We hereby look for Contractor ready to perform the service:
Evaluation of the antitumor activity of three compounds in a single experiment in the orthotopic GL261 model of glioma in mice